Quick Answer
Cadrenal Therapeutics, Inc. reported Net Income of -$13.24 million for fiscal year 2025.
Cadrenal Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net Income | -$13.24M -24.3% |
-$10.65M -27.5% |
-$8.36M -24.5% |
-$6.71M |
| Diluted EPS | -$6.64 +23.9% |
-$8.73 +6.0% |
-$9.29 -992.9% |
-$0.85 |
| Total Assets | $4.33M -57.3% |
$10.12M +18.8% |
$8.52M +994.8% |
$778.2K |
| Cash and Equivalents | $4.01M -60.0% |
$10.02M +19.2% |
$8.40M +25685.6% |
$32.6K |
| Stockholders Equity | $2.74M -63.2% |
$7.44M -3.3% |
$7.69M +238.6% |
-$5.55M |
| R&D Expense | $4.10M -2.5% |
$4.21M +40.2% |
$3.00M +663.6% |
$392.9K |
| Operating Income | -$13.46M -22.8% |
-$10.96M -43.6% |
-$7.63M -182.5% |
-$2.70M |
| Shares Outstanding | 2.34M +31.2% |
1.78M +105.3% |
868,184 -89.4% |
8.19M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$2.69M | -11.5% | +26.8% |
| Diluted EPS | September 30, 2025 | -$1.31 | +39.9% | +29.9% |
| Total Assets | September 30, 2025 | $4.09M | -12.6% | -31.6% |
| Cash and Equivalents | September 30, 2025 | $3.86M | — | -22.8% |
| Stockholders Equity | September 30, 2025 | $2.73M | -19.9% | -36.4% |
| R&D Expense | September 30, 2025 | $688.5K | -12.3% | -36.1% |
| Operating Income | September 30, 2025 | -$2.73M | -11.1% | +26.8% |
| Shares Outstanding | September 30, 2025 | 2.06M | +66.8% | +2.6% |
- Cadrenal Therapeutics, Inc. reported Net Income of -$13.24 million for fiscal year 2025.
- Cadrenal Therapeutics, Inc. showed a decrease of -24.3% in Net Income compared to the prior fiscal year.
- Cadrenal Therapeutics, Inc. reported Diluted EPS of $6.64 per share (loss) for fiscal year 2025.
- Cadrenal Therapeutics, Inc. showed an increase of +23.9% in Diluted EPS compared to the prior fiscal year.
- Cadrenal Therapeutics, Inc. reported Total Assets of $4.33 million for fiscal year 2025.
- Cadrenal Therapeutics, Inc. showed a decrease of -57.3% in Total Assets compared to the prior fiscal year.
- Cadrenal Therapeutics, Inc. reported Cash and Equivalents of $4.01 million for fiscal year 2025.
- Cadrenal Therapeutics, Inc. showed a decrease of -60.0% in Cash and Equivalents compared to the prior fiscal year.
- Cadrenal Therapeutics, Inc. reported Stockholders Equity of $2.74 million for fiscal year 2025.
- Cadrenal Therapeutics, Inc. showed a decrease of -63.2% in Stockholders Equity compared to the prior fiscal year.
- Cadrenal Therapeutics, Inc. reported R&D Expense of $4.10 million for fiscal year 2025.
- Cadrenal Therapeutics, Inc. showed a decrease of -2.5% in R&D Expense compared to the prior fiscal year.
- Cadrenal Therapeutics, Inc. reported Operating Income of -$13.46 million for fiscal year 2025.
- Cadrenal Therapeutics, Inc. showed a decrease of -22.8% in Operating Income compared to the prior fiscal year.
- Cadrenal Therapeutics, Inc. reported Shares Outstanding of 2.34 million shares for fiscal year 2025.
- Cadrenal Therapeutics, Inc. showed an increase of +31.2% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: